GlassScriptPhysician profile
Chelsey Kight
NPI 1669905741
$3,157.14
in general payments reported to CMS, 2019-2025
16 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $762 · 2022: $521 · 2023: $926 · 2024: $525 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $825.49 | 2021-2025 | Farxiga, Lokelma, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.55 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $280.38 | 2021-2024 | |
| Scpharmaceuticals INC. | $270.04 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $261.00 | 2021-2023 | Verquvo |
| Abbott Laboratories | $178.02 | 2022-2025 | Cardiomems |
| Vifor Pharma, INC. | $142.87 | 2021-2023 | Veltassa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $131.44 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $130.52 | 2021-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $122.95 | 2023-2025 | Onpattro, Amvuttra |
| Cvrx, INC. | $112.21 | 2023-2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $64.00 | 2023-2024 | Inpefa |
| Impulse Dynamics (USA) INC. | $23.62 | 2023 | Optimizer |
| Amgen INC. | $17.19 | 2022 | |
| Boston Scientific Corporation | $16.93 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $15.93 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsey Kight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.